Ikena Oncology, Inc.
IKNA
$1.11
-$0.015-1.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -87.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -87.91% |
| Cost of Revenue | -67.91% | -53.47% | -33.52% | -37.98% | -8.73% |
| Gross Profit | 66.36% | 49.38% | 22.59% | 5.80% | -33.62% |
| SG&A Expenses | -8.42% | -20.83% | -0.26% | 13.70% | 68.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.05% | -43.95% | -26.12% | -24.89% | 9.74% |
| Operating Income | 44.43% | 40.55% | 18.12% | -0.83% | -44.95% |
| Income Before Tax | 53.84% | 41.05% | 20.14% | -13.36% | -39.40% |
| Income Tax Expenses | 132.72% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.18% | 40.99% | 19.78% | -13.55% | -38.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.18% | 40.99% | 19.78% | -13.55% | -38.25% |
| EBIT | 44.43% | 40.55% | 18.12% | -0.83% | -44.95% |
| EBITDA | 44.05% | 40.27% | 17.54% | -0.92% | -44.95% |
| EPS Basic | 53.55% | 46.88% | 34.69% | 14.69% | -4.71% |
| Normalized Basic EPS | 55.91% | 51.14% | 38.21% | 28.48% | -5.56% |
| EPS Diluted | 53.55% | 46.88% | 34.69% | 14.69% | -4.71% |
| Normalized Diluted EPS | 55.91% | 51.14% | 38.21% | 28.48% | -5.56% |
| Average Basic Shares Outstanding | 0.80% | 11.10% | 22.82% | 33.10% | 32.03% |
| Average Diluted Shares Outstanding | 0.80% | 11.10% | 22.82% | 33.10% | 32.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |